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Epstein–Barr virus (EBV) belongs to the group of gamma-herpes viruses and was the first 
recognized human oncovirus. EBV is responsible for infectious mononucleosis and multiple 
lymphoid and epithelial malignancies including B-cell lymphomas (Burkitt lymphoma, 
Hodgkin lymphoma, and post-transplant lymphoproliferative disorder), various T-cell/
NK lymphoproliferative disorders, nasopharyngeal carcinoma, and gastric carcinoma, 
respectively. In addition, the presence of EBV has been documented in other cancers 
including breast, prostate, oral, and salivary gland carcinomas. The presence and role of 
EBV in cervical cancer and its precursor lesions (CIN) have also been described, but the 
results from the literature are inconsistent, and the causal role of EBV in cervical cancer 
pathogenesis has not been established yet. In the present review, we briefly surveyed 
and critically appraised the current literature on EBV in cervical cancer and its variants 
(lymphoepithelioma-like carcinoma) as well as its precursor lesions (CIN). In addition, we 
discussed the possible interactions between EBV and human papilloma virus as well as 
between EBV and immune checkpoint regulators (PD-L1). Though further studies are 
needed, the available data suggest a possible causal relationship between EBV and 
cervical cancer pathogenesis.
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iNTRODUCTiON
Infectious agents contribute to approximately 18% of all cancers worldwide (1). These agents 
include bacteria (e.g., Helicobacter pylori), viruses [human papilloma virus (HPV), hepatitis B virus, 
hepatitis C virus, Epstein–Barr virus (EBV), human herpes virus-8, human T-cell lymphotropic 
virus-1 (HTLV-1), and Merkel cell polyomavirus], and parasites (e.g., Schistosoma and liver flukes) 
(1–7). The cancers associated with the abovementioned infections include several hematologic 
{lymphomas/lymphoproliferative disorders [Hodgkin lymphoma (HL), Burkitt lymphoma, post-
transplant lymphoproliferative disorder, various T-cell/NK lymphoproliferative disorders]} and 
solid malignancies (carcinomas: nasopharyngeal, hepatocellular, gastric, cervical, Merkel cell, and 
bladder carcinoma). In addition, the presence of diverse microbial agents (e.g., viruses SV40, BK, 
JCV, and HTLV-II) has been described in many other cancer subtypes, but the results and causal 
relationships are inconsistent and inconclusive (7).
Viral infections are the most common cause of infection-related cancer agents (~12–15%) 
(4, 8). The vast majority of these infections occur in developing countries although the frequency is 
not negligible in developed world (5, 9). HPVs along with EBV are associated with 38% of all virus-
associated cancers (8). Most viral-associated cancers develop after long-term latency (15–40 years) 
(10). Notably, viral infections within the cancer cells are not mutually exclusive, and synergistic 
oncogenic effects can and likely occur (see also the paragraph on EBV in cervical cancer) (8, 11). 
FigURe 1 | Schematic outline showing a potential cooperation between Epstein–Barr virus (EBV) and human papilloma virus (HPV) oncoproteins to initiate cancer 
development and enhance malignancy progression. Efficient infection involves the activation of the PI3K/AKT, MAPK/ERK, JAK/STAT, β-catenin, and p53 pathways. 
As a result, NF-ĸB upregulation induces cell proliferation, epithelial–mesenchymal transition (EMT), and immune evasion through IFNγ-inducible PD-L1 expression.
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In addition, endemic forms of Burkitt lymphoma (mainly in 
equatorial Africa), an EBV-associated malignancy, are frequently 
linked to coinfection with the malaria-causing bacterium called 
Plasmodium falciparum (1).
eBv and Cancer
Epstein–Barr virus, previously known as human herpesvirus-4, 
is the first recognized human oncovirus. It belongs to the group 
of gamma-herpes viruses and is ubiquitously present in the adult 
population via salivary transmission (2). Upon infection, EBV 
typically remains in memory B-cells (Figure 1) in a latent phase, 
but may also be detected in epithelial cells (oropharynx) as well as 
in subsets of T-cells and NK-cells (2, 3, 5). EBV causes infectious 
mononucleosis and multiple lymphoid and epithelial malignan-
cies including B-cell lymphomas (Burkitt lymphoma, HL, and 
post-transplant lymphoproliferative disorder), various T-cell/NK 
lymphoproliferative disorders, and nasopharyngeal and gastric 
carcinomas (1, 12, 13).
The EBV genome is composed of double-stranded DNA, 
measuring approximately 172  kb in length (2). EBV encodes 
several viral oncogenes including EBV-encoded nuclear antigens 
[EBNA (1–3)] and the latent membrane proteins [LMP (1–2)] 
(14). Interactions of its surface protein gp350 with CD21 receptor 
and HLA class II on B-lymphocytes represent the major mecha-
nisms of the entrance into B-cells (Figure 1) (2). Upon primary 
infection and replication, most of its genes are turned off and the 
virus switches to the latent phase.
Molecular events related to EBV roles in cancer have been well 
described in HL and undifferentiated variants of nasopharyngeal 
carcinoma. Approximately 50% of HLs are EBV-positive, particu-
larly lymphocyte-depleted and mixed-cellularity variants of HL. 
Reed–Sternberg (RS) cells, typical B-transformed neoplastic 
cells in HL, are infected by EBV. RS activation and survival are 
largely dependent on NF-ĸB upregulation that is mediated by 
the interaction of CD40 receptor and LMP1 oncoprotein of EBV 
(Figure 1) (15). Other signaling pathways may also be activated 
by this interaction including MAPK/ERK, PIK3CA/AKT, JAK/
STAT, and Notch pathways (Figure  1) (2). Apart from LMP1 
oncoprotein, EBNA1 is another important EBV product that is 
required for the replication and maintenance of EBV genome 
(2). In the case of undifferentiated nasopharyngeal carcinoma, 
LMP1, LMP2, and EBNA1 products of EBV have been shown to 
promote cell growth and exert antiapoptotic effects in neoplastic 
cells (16), while LMPA2A prevents epithelial differentiation of the 
cells (14). They are also involved in cancer progression, invasion, 
and metastases as well as immune evasion, all the features that 
contribute to a highly aggressive behavior of nasopharyngeal car-
cinoma (16). Several recent studies also highlight novel mecha-
nisms on the complex interplay between viruses (including EBV 
and HPV), immune system, and carcinogenesis. Among these, 
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apolipoprotein B mRNA editing enzymes (APOBEC) family of 
deaminases appears to play a prominent role (17, 18). APOBEC 
family of enzymes, involved in the editing of DNA and/or RNA 
sequences, acts on the inner immune system against viruses and 
endogenous retroelements (19). A study of Kalchschmidt et al. 
showed that EBV (via its protein EBNA3C) may upregulate one 
of the APOBEC enzymes called activation-induced cytidine 
deaminase in EBV-infected B-lymphocytes (18). This may lead 
to somatic hypermutations at the IgH locus of B-lymphocytes and 
consequently induce progression of EBV-infected B-lymphocytes 
into neoplastic B-cells (lymphomas) (18). Similarly, Chen et al. 
demonstrated the importance of APOBEC enzymes in mediating 
the complex interactions between HPV infection, host immune 
system, and cervix during cervical cancer progression (17).
Epstein–Barr virus expression has also been described in 
several other solid malignancies including breast, prostate, oral, 
and salivary gland carcinomas (20–23).
Of note, EBV vaccines aimed to prevent primary infection 
and to treat EBV-related malignancies have been developed 
but still not approved (24, 25). The prophylactic vaccines have 
focused on EBV gp350 protein, which represents the major target 
of neutralizing antibodies while therapeutic vaccines targeted 
LMP2 and EBV nuclear antigen-1 (24). Thus, a phase 2 clinical 
trial conducted by Sokal et al. showed that the EBV vaccine had 
reduced the rate of infectious mononucleosis, but not the EBV 
infection (26). On the other hand, the studies have shown that the 
infusion of EBV-specific T cells may be effective in the treatment 
of EBV-associated malignancies such as HL and nasopharyngeal 
carcinoma (24). Given the frequency of EBV-associated cancers, 
the EBV vaccines are urgently needed.
ROLe OF eBv iN CeRviCAL CANCeR: 
POSSiBLe ONCOgeNiC eFFeCTS OF 
HPv/eBv iNTeRACTiONS
Cervical cancer is the fourth-most common and fourth-most 
deadly female malignancy worldwide (27, 28). In developing 
countries, it is the most common cancer subtype and the third 
leading cancer-mortality causes (28). The vast majority (more 
than 95%) of the cervical cancers (squamous cell carcinomas 
and adenocarcinomas) has been attributed to the infection with 
high-risk HPVs (14, 27), which are now considered a major cause 
of cervical cancer (12). Numerous high-risk HPVs have been 
linked to cervical cancer including HPV types 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, and 59 (these viruses are allocated by IARC 
in Group 1 given that their carcinogenicity has been sufficiently 
demonstrated) (7). However, most common (~70%) HPV types 
involved in cervical carcinogenesis are HPV16 and 18 (29). It is 
well known that high-risk HPVs act via their proteins E6 and E7 
that interact with p53 and pRb affecting the cell cycle, apoptosis, 
and cell adhesion (Figure 1) (11, 29, 30).
Previous data indicate that other infectious agents may also be 
actively involved in cervical carcinogenesis (12). Among these, 
EBV appears to be one of the most relevant. Some, but not all 
early studies, published more than two decades ago, offered the 
evidence of EBV DNA presence in both precancerous (CIN) and 
invasive cervical carcinoma cells (31–34), suggesting its possible 
role in the pathogenesis of cervical carcinoma. Other studies 
revealed the presence of EBV in inflammatory, but not in cervical 
cancer cells (35–39).
A recently published meta-analysis (12), based on 25 publica-
tions, revealed the pooled prevalence of EBV in cervical cancer 
to be 43.63%, which was significantly higher in comparison with 
healthy controls (19%). In addition, EBV expression gradually 
increased from 27% (CIN1) to 35% (CIN2/3). EBV coinfection 
with HPV also posed a fourfold increased risk of cervical cancer 
in EBV-positive women (12); similarly, precancerous cervical 
lesions were twice as common in EBV-positive women com-
pared with EBV-negative cases (12). Taken together, these data 
indicate EBV as a potentially active cofactor (not only passenger/
bystander) in the cervical cancer pathogenesis and progression.
Most cervical carcinomas are invasive squamous cell car-
cinomas (keratinizing and non-keratinizing types). However, 
many other subtypes have been recognized including lymphoe-
pithelioma-like carcinoma (LELC) of the cervix (40). LELC is 
a poorly differentiated (non-keratinizing) cervical carcinoma 
with rich inflammatory stroma, composed predominantly of 
T-lymphocytes (CD4+ and CD8+) with minor component of 
B-lymphocytes (CD20+ and CD79a+) and NK-cells (CD56+) 
(41–43). It is a distinct variant of cervical carcinoma that may 
also be associated with HPV infection (44) although some studies 
revealed no HPV infection in LELC (43, 45). Morphologically, it 
is similar to its nasopharyngeal counterpart that is a prototype of 
cancer associated with EBV infection (46). LELC exhibits some 
unique clinicopathologic characteristics including affection of 
younger patients, presentation at earlier stage, and more favorable 
outcome compared with conventional cervical carcinoma (45, 47). 
Although some studies reported association of LELC with EBV 
infection in Asian women (47, 48), other studies failed to confirm 
this observation including other ethnic groups (e.g., Caucasians) 
(44, 49–54). In addition, the study of Chao et al. using real-time 
PCR and EBV-encoded RNA in  situ hybridization revealed the 
EBV sequences in a florid inflammatory stromal component, 
but not in poorly differentiated squamous cells of LELC (45). 
In contrast, EBV presence has been documented in neoplastic 
cells of the lymphoepithelial carcinomas at other locations (e.g., 
salivary and lacrimal glands, middle ear, larynx, pancreas, and 
esophagus) (55–60).
In addition, EBV infection has been demonstrated in several 
lymphoproliferative lesions of the cervix, e.g., lymphoma-like 
lesions (35, 61, 62) and extranodal NK/T-cell lymphoma (63).
HPv and eBv in Cervical Cancer
One of the most intriguing research issues is the possible syner-
gistic effects of HPVs and EBV in promoting cervical carcino-
genesis and progression. Such synergism and coinfections have 
already been observed in nasopharyngeal carcinoma, particularly 
the variant from the endemic regions (China and Southeast Asia) 
(14) and oral squamous cell carcinoma (11, 64).
A recent meta-analysis of de Lima et al. (12) revealed a HPV/
EBV coinfection rate in cervical carcinoma to be ~29%. They also 
found a positive association between EBV load and lesion grade 
(from CIN1 to CIN3 and invasive cancer), indicating a potential 
FigURe 2 | A tissue microarray sample of cervical cancer associated with CIN3 lesion exhibiting strong positivity for Epstein–Barr virus (latent membrane protein 1 
antibody) (immunohistochemistry, 10×).
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causal role of EBV in cervical carcinogenesis and progression 
(an illustration of EBV positivity in CIN3 lesion and cervical 
carcinoma is shown in Figure 2). One of the possible scenarios 
is a transformation of cervical cells via C3d complement receptor 
that is widely expressed in cervix, making cervical cells more 
sensitive to various oncogenic stimuli (8). EBV presence in cer-
vix may also accelerate integration of HPV genome into cervical 
cell’s genome, enhancing genomic instability of the infected 
cervical cells (65). In addition, chronic cervicitis, a common 
condition during female reproductive life, may also facilitate the 
EBV infection and its potential oncogenic effects (8). We have 
also proposed that viruses alone or in collaboration may induce 
oncogene activation and promote the epithelial–mesenchymal 
transition, one of the key steps in cancer progression and meta-
stasis (Figure 1) (66).
As correctly observed in the meta-analysis of de Lima et al. (12), 
EBV along with cytomegalovirus (CMV) may also be detected 
in cervical secretions and uterine cervix from healthy young 
women. Several studies confirmed the frequency of EBV and 
CMV in cervical secretions among healthy women to be between 
10 and 30% (67–70). Such findings may also be clinically relevant 
given that viruses such as CMV, HSVs, and varicella zoster may 
cause congenital, perinatal, or neonatal infections (67). The role 
of vertical transmission of EBV is still uncertain although rare 
cases of congenital EBV infection have been reported (71, 72).
The discrepant data on EBV positivity rate in cervical may 
be caused by the different diagnostic assays, the sample type, 
and other technical issues that may affect the results (e.g., auto-
mated vs. manual detecting system) (73). Thus, PCR is a highly 
sensitive method, but it cannot discriminate between neoplastic 
(epithelial) and stromal/inflammatory cells (e.g., B-lymphocytes) 
giving the false-positive results (74) while in  situ hybridization 
and immunohistochemical assays (e.g., ISH RNA and specific 
antibodies against EBV antigens, see Figure  2) may be more 
helpful to precisely identify the viral load in the specific cell com-
partments. Of note, most studies exploring and reporting EBV 
positivity in cervical carcinoma used only PCR-based assays 
(65, 75–78). One study reported EBV positivity by PCR in CIN3 
lesions and cervical carcinoma in 15 and 5.8%, respectively, 
while ISH RNA (EBER) revealed no EBV positivity (0%) in any 
of the tested samples (79). This led the authors to conclude that 
EBV plays little role in the pathogenesis of cervical carcinoma 
in their population (79). Similarly, another study reported EBV 
positivity in 40/58% (69%) of cervical carcinoma samples by PCR 
while immunohistochemistry (LMP1 protein) revealed EBV 
positivity in only 26% of tested samples (n = 23) (80). In contrast, 
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Szkaradkiewicz et  al. reported a significantly higher detection 
rate of EBV positivity among CIN3 lesions by ISH (70%) in 
comparison with PCR-based assay (30%), but the sample size 
was small (n = 10) (68). Of note, many of the reported studies 
employed small number of cases (e.g., McCormick used 18 inva-
sive carcinoma samples while Aromseree et  al. used only four 
invasive carcinoma samples for ISH assay). On the other hand, 
commercially available immunohistochemical assays (e.g., anti-
bodies against EBNA1 or LMP1 proteins) may be affected by the 
antibody specificity and sensitivity and preanalytical issues (tis-
sue fixation and processing). In all detection assays, differences 
in sample preparation (cytology: cell block vs. cytospin, biopsy: 
small vs. surgical; frozen tissue vs. formalin-fixed tissue) and 
sampling technique (swab, spatula, or cytobrush) may also have 
a significant impact on the obtained results and may account for 
the reported discrepancies (12, 76, 81).
interplay Between PD-L1 and eBv in 
Cervical Carcinoma and Other eBv-
Related Malignancies
Recent breakthrough advances in cancer treatment are mainly 
due to the therapeutic effects of immune checkpoint inhibitors 
[such as anti-programmed cell death-1 (PD-1)/PD-L1] that 
have revolutionized management of several cancers including 
non-small-cell lung carcinoma, renal cell carcinoma, advanced 
urothelial carcinoma, Merkel cell carcinoma, microsatellite 
instable (MSI-H) colorectal carcinoma, malignant melanoma, 
and classical HL (82–84). The interaction between PD-1 and its 
ligand PD-L1 enables cancer cells to escape T-cell-mediated cel-
lular cytotoxicity by suppressing the function of T-lymphocytes. 
Numerous studies have described the mechanisms of PD-L1 
activation in tumor cells (85). One of the mechanisms of PD-L1 
upregulation may be via EBV in EBV-associated malignancies 
such as gastric carcinoma and classical HL (86, 87). Thus, in 
the case of EBV+ gastric carcinomas, EBNA1 may induce both 
constitutive and IFNγ-inducible PD-L1 expression in EBV (+) 
gastric carcinoma cells (Figure 1) (86). Compared with EBV (−) 
gastric cells, EBV (+) gastric cells showed significantly higher 
PD-L1 expression by activating the JAK2/STAT1/IRF-1 signaling 
pathway (86). On the other hand, activation of inhibitory PD-1/
PD-L1 axis may allow for immune evasion of EBV-associated 
cancer cells (Figure 1) (88). In contrast, two separate studies on 
nasopharyngeal carcinoma revealed tumor cells’ PD-L1 expres-
sion in 44 and 64% of the cases, respectively, but PD-L1 status was 
not associated with EBV viral load (89, 90).
PD-L1 expression has been described in substantial pro-
portion of cervical carcinomas (both squamous cell and adeno -
carcinomas) and precursor (CIN) lesions of the cervix (91–93). 
A study of Yang-Chun et  al. (93) demonstrated a positive 
association between HPV and PD-L1 status in CIN lesions and 
invasive cervical carcinoma. The status of PD-L1 in LELC of 
cervix is unknown as no studies are available at present. The data 
on pulmonary LELC indicate PD-L1 expression in cancer cells 
and a favorable therapeutic response to a PD-1 inhibitor nivolumab 
(94, 95). Though by no means conclusive, the little available 
data presented in these studies provide speculative fuel to the 
notion that there might be an important interplay between 
immune checkpoint proteins and EBV in cervical and possibly 
other cancers. However, further studies are needed to precisely 
identify any interplay between EBV and PD-L1 in CIN lesions 
and cervical carcinomas.
CONCLUSiON AND FUTURe DiReCTiONS
Epstein–Barr virus infections play a prominent role in cancer 
initiation and progression in several human malignancies 
including several lymphomas (both B- and T-cell lineages) and 
carcinomas (nasopharyngeal and gastric). Current evidence 
suggests a possible causal relationship between EBV and cervical 
cancer pathogenesis. A commonly present coinfection of EBV 
and HPV in cervical cancer (such as oral cancer) also indicates 
a potential oncogenic interplay between the two viruses. More 
studies (both basic/experimental and clinical/observational 
with larger sample size) are necessary to elucidate the oncogenic 
relevance of the copresence and its clinical impact. The lack of 
basic studies on PD-L1 and EBV interplay in cervix also merits 
further research. Given the success of cervical cancer preven-
tion through HPV vaccination and upcoming EBV vaccine, 
additional molecular and translational/clinical studies on EBV 
are necessary to allow for the further improvements in its pre-
vention, particularly in developing countries that are affected 
by the highest rates of infections (HPV and EBV) and cervical 
cancer burden.
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